Drug intelligence / Profile preview

TQB3473

Development stage: Phase 3
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3473 is a novel, potent, and highly selective oral spleen tyrosine kinase (Syk) inhibitor developed for the treatment of immune-mediated diseases. It is designed to target B cell receptor (BCR) pathways and Fcγ receptors, which are critical in the pathogenesis of various hematological malignancies and autoimmune disorders. The drug is being investigated primarily for relapsed or refractory hematological malignancies and primary immune thrombocytopenia (ITP). Clinical studies have shown that TQB3473 demonstrates preliminary efficacy with a favorable safety profile in these patient populations[1][2][4][6].

Targets

SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on TQB3473.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3473.

Explore the full profile